share_log

BRIEF-Humanigen Announces Positive Results From Phase 1 Study Of Ifabotuzumab In Glioblastoma Multiforme

BRIEF-Humanigen Announces Positive Results From Phase 1 Study Of Ifabotuzumab In Glioblastoma Multiforme

Brief-Humanigen宣布Ifaotuzumab治疗多形性胶质母细胞瘤的第一阶段研究取得积极结果
路透社 ·  2021/04/09 19:04

April 9 (Reuters) - Humanigen Inc :
   * HUMANIGEN ANNOUNCES POSITIVE RESULTS FROM PHASE 1 STUDY OF IFABOTUZUMAB IN GLIOBLASTOMA MULTIFORME
   * HUMANIGEN INC - PHASE 1 DOSE ESCALATION AND BIOIMAGING STUDY SHOWS THAT IFABOTUZUMAB DEMONSTRATES HIGHLY SPECIFIC TUMOR TARGETING IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)

路透4月9日电-Humanigen Inc:*HUMANIGEN宣布IFABOTUZUMAB治疗多形性胶质母细胞瘤的第一阶段研究取得积极结果*HUMANIGEN INC-1期剂量递增和生物成像研究表明,IFABOTUZUMAB在复发性多形性胶质母细胞瘤患者中显示出高度特异性的肿瘤靶向性Eikon的源文本:进一步的公司报道:(Reurs.Briefs@thomsonreurs.com;)

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发